Shanghai Haohai Biotech FY26 H1 net profit drops 46.64% to RMB 112.63 million; revenue falls 9.81% to RMB 1.17 billion

PUBT · 1d ago
Shanghai Haohai Biotech FY26 H1 net profit drops 46.64% to RMB 112.63 million; revenue falls 9.81% to RMB 1.17 billion
  • Shanghai Haohai Biological Technology revenue fell 9.81% to RMB 1.17 billion for the six months ended June 30, 2026.
  • Net profit attributable to shareholders dropped 46.64% to RMB 112.63 million; basic earnings per share slid to RMB 0.49.
  • Gross margin narrowed 4.96 percentage points to 65.15% on a weaker mix, led by a sharp HA Dermal Filler decline.
  • Medical aesthetics and wound care revenue sank 23.95% to RMB 435.99 million; HA Dermal Filler sales tumbled 41.59% to RMB 202.01 million.
  • Regeneration and repair products contributed RMB 61.09 million in new revenue; interim dividend cut to RMB 0.25 per share.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Haohai Biological Technology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260907-12322846), on September 07, 2026, and is solely responsible for the information contained therein.